Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna

Clin Infect Dis. 2018 Aug 16;67(5):795-798. doi: 10.1093/cid/ciy279.

Abstract

The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Austria
  • Bacteremia / drug therapy
  • Endocarditis, Bacterial / drug therapy*
  • Female
  • Gram-Positive Bacterial Infections / blood
  • Gram-Positive Bacterial Infections / drug therapy*
  • Hospitals, General
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Teicoplanin / analogs & derivatives*
  • Teicoplanin / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Teicoplanin
  • dalbavancin